Malignant germ cell tumors of the ovary: a review of 41 cases and risk factors for recurrence

Objective: To review the outcome of treatment in patients with malignant ovarian germ cell tumors and to define the risk factors for recurrence. Material and methods: Forty-one patients with malignant ovarian germ cell tumors were reviewed retrospectively. Survival time and survival rate were obtained. Risk factors such as stage, histological type, and type of operation were evaluated for reccurrence. Results: Twenty-three (56%) had dysgerminomas, eight (19.5%) had mixed germ cell tumors, three (7.3%) had yolk sac tumors, three (7.3%) had immature teratomas, two (4.8%) had squamous cell carcinoma arising from a mature teratoma, one (2.4%) had embryonal carcinoma and one choriocarcinoma. Most of the cases (73%) were in Stage I. Twenty-nine patients (70.7%) underwent conservative surgery and 12 patients (29.3%) had at least bilateral salpingo-oophorectomy. Thirty patients were operated on optimally with surgical staging and 11 suboptimally. Seven patients (17%) had recurrence after remission. The overall survival time was 187 +/- 8.43 months for all cases, 195 +/- 8.49 for dysgerminoma and 161 +/- 10.96 for non-dysgerminoma cases with a median follow-up time of 98.52 (8-204) months. Non-dysgerminoma histologic type, being operated on suboptimally and radically, and advanced tumor stage have been found to be risk factors for recurrence. Conclusion: Regardless of histologic types and stages the prognosis of germ cell tumors are satisfactory with current therapeutic strategies.

Malignant germ cell; Recurrence; Ovary; Risk factors

[1] Disaia P., Creasman W.: “Germ cell, stromal and other ovarian tumors”. In: Disaia P., Creasman W. (eds.). Clinical Gynecologic Oncology, St. Louis: Mosby-Year Book, 1997, 351.

[2] Low J.J., Perrin L.C., Lewis C.P., Crandon A.J., Hacker N.F.: “A review of 74 cases. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors”. Cancer, 2000, 89, 391.

[3] Zanetta G., Bonazzi C., Cantu M.G., Binidagger S., Locatelli A., Bratina G. et al.: “Survival and reproductive function after treatment of malignant germ cell ovarian tumors”. J. Clin. Oncol., 2001, 19, 1015.

[4] Schwartz P.: “Combination chemotherapy in the management of ovarian germ cell malignancies”. Obstet. Gynecol., 1984, 64, 564.

[5] Gershenson D.M., Morris M., Cangir A., Kavanagh J.J., Stringer C.A., Edwards C.L. et al.: “Treatment of malignant germ cell tumors of the ovary with Bleomycin, etoposide, and cisplatin”. J. Clin. Oncol., 1990, 8, 71.

[6] Billmire D., Vinocur C., Rescorla F., Cushing B., London W., Sclatter M. et al.: “Childern’s Oncology Group (COG). Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study”. J. Pediatr. Surg., 2004, 39, 424.

[7] Peccatori F., Bonazzi C., Chiari S., Landoni F., Colombo N., Mangioni C.: “Surgical management of malignant ovarian germ-cell tumors: 10 years’ experience of 129 patients”. Obstet. Gynecol., 1995, 86, 367.

[8] De Backer A., Madern G.C., Oosterhuis J.W., Hakvoort-Cammel F.G., Hazerbroek F.W.: “Ovarian germ cell tumors in children: a clinical study of 66 patients”. Pediatr. Blood Cancer, 2006, 46, 459.

[9] Zhang R., Hong W., Liu L.: “Treatment of malignant germ cell tumors of the ovary: a clinical analysis of 233 cases”. Zhonghua Zhong Liu Za Zhi., 1998, 20, 155.

[10] International Federation of Gynecology and Obstetrics: “Change in definitions of clinical staging for carcinoma of the cervix and the ovary”. Am. J. Obstet. Gynecol., 1987, 156, 236.

[11] Scully R.E.: “Histological typing of ovarian tumors”. In: International histological classification of tumors. Geneva: World Health Organization and Springer-Verlag, 1999.

[12] Gershenson D.M., Peccatori F., Bonazzi C., Chiari S., Landoni F., Colombo N., Mangioni C.: “Update on malignant ovarian germ cell tumors”. Cancer, 1993, 71 (suppl. 4), 1581.

[13] Herrin V.E., Thigpen J.T.: “Germ cell tumors of the ovary”. In: Raghavan D., Breecher M.L., Johnson D.H., Meropol N.J., Moots P.L., Thigpen J.T. (eds.). Textbook of Uncommon Cancers, 2nd edition, 1999, West Sussex, John Wiley & Sons.

[14] Tewari K., Cappuccini F., DiSaia P.J., Bermon M.L., Monetta A., Kohler M.F..: “Malignant germ cell tumors of the ovary”. Obstet. Gynecol., 2000, 95, 128.

[15] Gueye A., Narducci F., Baranzelli M.C., Collinet P., Farine O., Fournier C. et al.: “Malignant ovarian germ cell tumors: a trial of 36 cases”. Gynecol. Obstet. Fertil., 2007, 35, 406.

[16] Kurman R., Norris H.: “Malignant germ cell tumors of the ovary”. Hum. Pathol., 1977, 8, 551.

[17] Schwartz P., Chambers S., Chambers J., Kohorn E., McIntosh S.: “Ovarian germ cell malignancies: The Yale University experience”. Gynecol. Oncol., 1992, 45, 26.

[18] Williams S., Blessing J.A., Liao S.Y., Ball H., Hanjani P.: “Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group”. J. Clin. Oncol., 1994, 12, 701.

[19] El-Lamie I.K., Shehata N.A., Abou-Loz S.K., El-Lamie K.I.: “Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University”. Eur. J. Gyneacol. Oncol., 2000, 21, 605.

[20] Tangir J., Zelterman D., Ma W., Schwartz Peter P.E.: “Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary”. Obstet. Gynecol., 2003, 101, 251.